Haemostatic effects of polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits

Y. Okamura, T. Fujie, M. Nogawa, H. Maruyama, M. Handa, Y. Ikeda, S. Takeoka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Our purpose was to produce a platelet substitute that could enhance haemostatic ability using rabbits with severe thrombocytopenia. We have developed polymerized albumin particles (polyAlb) for treatment of bleeding and focused on a dodecapeptide, HHLGGAKQAGDV (H12), as a useful ligand for activated platelet. This sequence occurs only at the carboxy-terminus of the fibrinogen γ-chain (γ 400-411). H12 was conjugated to the surface of polyAlb modified with poly(ethylene glycol) (PEG) chains to produce blood-compatible particles (H12-PEG-polyAlb) that had prolonged blood residence time and enhanced stability in vitro and in vivo. The H12-PEG-polyAlb was administered intravenously to rabbits with severe thrombocytopenia, and the ear bleeding time was measured in order to evaluate the haemostatic effect. The H12-PEG-polyAlb significantly shortened the ear bleeding time of severely thrombocytopenic rabbits and showed no effect on the inhibition or promotion of endogenous and exogenous coagulation activities. Furthermore, we could assess the haemostatic capacity of the H12-PEG-polyAlb, based on the relationship between transfused platelet count and the bleeding time. The H12-PEG-polyAlb may be a suitable candidate for an alternative to human platelet concentrates infused to treat bleeding in patients with severe thrombocytopenia.

Original languageEnglish
Pages (from-to)158-166
Number of pages9
JournalTransfusion Medicine
Volume18
Issue number3
DOIs
Publication statusPublished - 2008 Jun

Fingerprint

Hemostatics
Fibrinogen
Albumins
Blood Platelets
Rabbits
Bleeding Time
Thrombocytopenia
Ear
Hemorrhage
Ethylene Glycol
Platelet Count
Ligands

Keywords

  • Dodecapeptide (H12)
  • Ear bleeding time
  • PEG modification
  • Platelet substitutes
  • Polymerized albumin particles
  • Thrombocytopenic rabbits

ASJC Scopus subject areas

  • Immunology

Cite this

Haemostatic effects of polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits. / Okamura, Y.; Fujie, T.; Nogawa, M.; Maruyama, H.; Handa, M.; Ikeda, Y.; Takeoka, S.

In: Transfusion Medicine, Vol. 18, No. 3, 06.2008, p. 158-166.

Research output: Contribution to journalArticle

Okamura, Y. ; Fujie, T. ; Nogawa, M. ; Maruyama, H. ; Handa, M. ; Ikeda, Y. ; Takeoka, S. / Haemostatic effects of polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits. In: Transfusion Medicine. 2008 ; Vol. 18, No. 3. pp. 158-166.
@article{9b373e72500e4c87a91f77446190592a,
title = "Haemostatic effects of polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits",
abstract = "Our purpose was to produce a platelet substitute that could enhance haemostatic ability using rabbits with severe thrombocytopenia. We have developed polymerized albumin particles (polyAlb) for treatment of bleeding and focused on a dodecapeptide, HHLGGAKQAGDV (H12), as a useful ligand for activated platelet. This sequence occurs only at the carboxy-terminus of the fibrinogen γ-chain (γ 400-411). H12 was conjugated to the surface of polyAlb modified with poly(ethylene glycol) (PEG) chains to produce blood-compatible particles (H12-PEG-polyAlb) that had prolonged blood residence time and enhanced stability in vitro and in vivo. The H12-PEG-polyAlb was administered intravenously to rabbits with severe thrombocytopenia, and the ear bleeding time was measured in order to evaluate the haemostatic effect. The H12-PEG-polyAlb significantly shortened the ear bleeding time of severely thrombocytopenic rabbits and showed no effect on the inhibition or promotion of endogenous and exogenous coagulation activities. Furthermore, we could assess the haemostatic capacity of the H12-PEG-polyAlb, based on the relationship between transfused platelet count and the bleeding time. The H12-PEG-polyAlb may be a suitable candidate for an alternative to human platelet concentrates infused to treat bleeding in patients with severe thrombocytopenia.",
keywords = "Dodecapeptide (H12), Ear bleeding time, PEG modification, Platelet substitutes, Polymerized albumin particles, Thrombocytopenic rabbits",
author = "Y. Okamura and T. Fujie and M. Nogawa and H. Maruyama and M. Handa and Y. Ikeda and S. Takeoka",
year = "2008",
month = "6",
doi = "10.1111/j.1365-3148.2008.00860.x",
language = "English",
volume = "18",
pages = "158--166",
journal = "Transfusion Medicine",
issn = "0958-7578",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Haemostatic effects of polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits

AU - Okamura, Y.

AU - Fujie, T.

AU - Nogawa, M.

AU - Maruyama, H.

AU - Handa, M.

AU - Ikeda, Y.

AU - Takeoka, S.

PY - 2008/6

Y1 - 2008/6

N2 - Our purpose was to produce a platelet substitute that could enhance haemostatic ability using rabbits with severe thrombocytopenia. We have developed polymerized albumin particles (polyAlb) for treatment of bleeding and focused on a dodecapeptide, HHLGGAKQAGDV (H12), as a useful ligand for activated platelet. This sequence occurs only at the carboxy-terminus of the fibrinogen γ-chain (γ 400-411). H12 was conjugated to the surface of polyAlb modified with poly(ethylene glycol) (PEG) chains to produce blood-compatible particles (H12-PEG-polyAlb) that had prolonged blood residence time and enhanced stability in vitro and in vivo. The H12-PEG-polyAlb was administered intravenously to rabbits with severe thrombocytopenia, and the ear bleeding time was measured in order to evaluate the haemostatic effect. The H12-PEG-polyAlb significantly shortened the ear bleeding time of severely thrombocytopenic rabbits and showed no effect on the inhibition or promotion of endogenous and exogenous coagulation activities. Furthermore, we could assess the haemostatic capacity of the H12-PEG-polyAlb, based on the relationship between transfused platelet count and the bleeding time. The H12-PEG-polyAlb may be a suitable candidate for an alternative to human platelet concentrates infused to treat bleeding in patients with severe thrombocytopenia.

AB - Our purpose was to produce a platelet substitute that could enhance haemostatic ability using rabbits with severe thrombocytopenia. We have developed polymerized albumin particles (polyAlb) for treatment of bleeding and focused on a dodecapeptide, HHLGGAKQAGDV (H12), as a useful ligand for activated platelet. This sequence occurs only at the carboxy-terminus of the fibrinogen γ-chain (γ 400-411). H12 was conjugated to the surface of polyAlb modified with poly(ethylene glycol) (PEG) chains to produce blood-compatible particles (H12-PEG-polyAlb) that had prolonged blood residence time and enhanced stability in vitro and in vivo. The H12-PEG-polyAlb was administered intravenously to rabbits with severe thrombocytopenia, and the ear bleeding time was measured in order to evaluate the haemostatic effect. The H12-PEG-polyAlb significantly shortened the ear bleeding time of severely thrombocytopenic rabbits and showed no effect on the inhibition or promotion of endogenous and exogenous coagulation activities. Furthermore, we could assess the haemostatic capacity of the H12-PEG-polyAlb, based on the relationship between transfused platelet count and the bleeding time. The H12-PEG-polyAlb may be a suitable candidate for an alternative to human platelet concentrates infused to treat bleeding in patients with severe thrombocytopenia.

KW - Dodecapeptide (H12)

KW - Ear bleeding time

KW - PEG modification

KW - Platelet substitutes

KW - Polymerized albumin particles

KW - Thrombocytopenic rabbits

UR - http://www.scopus.com/inward/record.url?scp=45349083291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349083291&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3148.2008.00860.x

DO - 10.1111/j.1365-3148.2008.00860.x

M3 - Article

C2 - 18598278

AN - SCOPUS:45349083291

VL - 18

SP - 158

EP - 166

JO - Transfusion Medicine

JF - Transfusion Medicine

SN - 0958-7578

IS - 3

ER -